Revance Therapeutics Inc (RVNC)
3.47
+0.18
(+5.47%)
USD |
NASDAQ |
Apr 26, 14:16
Revance Therapeutics Total Liabilities (Quarterly): 630.06M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 630.06M |
| September 30, 2023 | 638.69M |
| June 30, 2023 | 570.75M |
| March 31, 2023 | 574.47M |
| December 31, 2022 | 569.30M |
| September 30, 2022 | 565.88M |
| June 30, 2022 | 564.51M |
| March 31, 2022 | 614.00M |
| December 31, 2021 | 462.69M |
| September 30, 2021 | 461.67M |
| June 30, 2021 | 454.64M |
| March 31, 2021 | 431.70M |
| December 31, 2020 | 345.93M |
| September 30, 2020 | 339.29M |
| June 30, 2020 | 320.46M |
| March 31, 2020 | 284.55M |
| December 31, 2019 | 114.80M |
| September 30, 2019 | 114.53M |
| June 30, 2019 | 107.35M |
| March 31, 2019 | 103.37M |
| December 31, 2018 | 80.73M |
| September 30, 2018 | 50.95M |
| Date | Value |
|---|---|
| June 30, 2018 | 49.27M |
| March 31, 2018 | 48.14M |
| December 31, 2017 | 26.85M |
| September 30, 2017 | 27.13M |
| June 30, 2017 | 27.66M |
| March 31, 2017 | 30.78M |
| December 31, 2016 | 27.29M |
| September 30, 2016 | 26.14M |
| June 30, 2016 | 21.23M |
| March 31, 2016 | 22.15M |
| December 31, 2015 | 22.57M |
| September 30, 2015 | 23.16M |
| June 30, 2015 | 22.38M |
| March 31, 2015 | 12.26M |
| December 31, 2014 | 16.10M |
| September 30, 2014 | 21.01M |
| June 30, 2014 | 24.81M |
| March 31, 2014 | 28.22M |
| December 31, 2013 | 180.19M |
| September 30, 2013 | 41.16M |
| December 31, 2012 | 230.15M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
107.35M
Minimum
Jun 2019
638.69M
Maximum
Sep 2023
429.75M
Average
461.67M
Median
Sep 2021
Total Liabilities (Quarterly) Benchmarks
| AbbVie Inc | 124.31B |
| Alnylam Pharmaceuticals Inc | 4.051B |
| Ionis Pharmaceuticals Inc | 2.603B |
| Madrigal Pharmaceuticals Inc | 235.21M |
| Vertex Pharmaceuticals Inc | 5.150B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 478.45M |
| Shareholders Equity (Quarterly) | -151.60M |
| Debt to Equity Ratio | -2.830 |
| Current Ratio | 3.798 |
| Net Debt Paydown Yield | -1.30% |